

# NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

NCT05996003

---

|            |                 |
|------------|-----------------|
| Status     | RECRUITING      |
| Phase      | Phase 2         |
| Sponsor    | NS Pharma, Inc. |
| Enrollment | 20 participants |

## Key Eligibility Criteria

---

### Inclusion (5)

- Male 4 years and <15 years of age
- Confirmed DMD mutation(s) in the dystrophin gene that is amenable to skipping of exon 44 to restore the dystrophin mRNA reading frame
- Able to walk independently without assistive devices
- Ability to complete the TTSTAND without assistance in <20 seconds
- Stable dose of glucocorticoid for at least 3 months and the dose is expected to remain on a stable dose for the duration of the study.

### Exclusion (7)

- Has a body weight of <20 kg at the time of informed consent (applies to participants screening for Part 1 only)
- Evidence of symptomatic cardiomyopathy
- Current or previous treatment with anabolic steroids (e.g., oxandrolone) or products containing resveratrol or adenosine triphosphate within 3 months prior to first dose of study drug
- Current or previous treatment with any other investigational drug within 3 months prior to the first dose of study drug or within 5 times the half-life of a medication, whichever is longer
- Surgery within the 3 months prior to the first dose of study drug or planned during the study duration
- ... and 2 more (see full listing online)

## Locations (25 total)

---

Children's Hospital Colorado, Aurora, Colorado, United States  
Rare Disease Research, LLC - FL, Kissimmee, Florida, United States  
Rare Disease Research, Atlanta, Georgia, United States  
... and 22 more locations